IL13 and asthma: Indeed, two sequential large phase 3 clinical trials did not establish the utility of FeNO in anti-IL-13 biologic therapy; although high FeNO subgroups enjoyed significant reductions in annualized asthma exacerbations in STRATOS1, this finding was not replicated in STRATOS2 [59].